Vyome Q3 2025 Earnings Report

Vyome EPS Results

• Actual EPS: -$3.12
• Consensus EPS: N/A
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Vyome Revenue Results

• Actual Revenue: $0.04 million
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Vyome Announcement Details

• Quarter: Q3 2025
• Date: 11/14/2025
• Time: After Market Closes
• Conference Call Date: Thursday, November 20, 2025
• Conference Call Time: 10:00AM ET

ReShape Lifesciences Inc., a medical device company, provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company's product portfolio includes Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy; and ReShape Vest system, an investigational, minimally invasive, laparoscopically implanted medical device that wraps around the stomach to enable weight loss in obese and morbidly obese patients without cutting or permanently removing portions of the stomach, or bypassing any portion of the gastrointestinal tract. It also offers ReShapeCare virtual health coaching program, a virtual telehealth weight management program that supports healthy lifestyle changes for all medically managed weight-loss patients; and ReShape Diabetes Bloc-Stim Neuromodulation, a technology that is in preclinical development for the treatment of type 2 diabetes mellitus. In addition, the company provides Obalon Balloon System, a swallowable capsule used to track and display the location of the balloon during placement. The company was formerly known as EnteroMedics Inc. and changed its name to ReShape Lifesciences Inc. in 2017. ReShape Lifesciences Inc. was incorporated in 2002 and is headquartered in San Clemente, California.

Vyome Q3 2025 Earnings Call Transcript

Key Takeaways

• Positive Sentiment: VT1953 interim Phase 2 results showed a significant reduction in malodor and lesion pain, improved quality of life, no clinically significant adverse events, and full Phase 2 data are expected in December 2025 — positioning it as a potential orphan therapy for malignant fungating wounds with a ~ $1 billion U.S. addressable market.
• Positive Sentiment: VT1908 demonstrated strong preclinical efficacy in anterior uveitis with steroid-comparable results, and the company plans FDA interactions in H1 2026 to advance toward clinical readiness.
• Neutral Sentiment: The company reported approximately $5.7 million in cash and short-term investments, which management says provides a runway through 2026, while Q3 net loss was $9.2 million that included one-time transaction and non-cash financing charges.
• Positive Sentiment: Vyome completed a streamlined NASDAQ listing with a 100% common stock structure (no preferred stock, warrants, or convertibles), strengthened leadership with senior hires from big pharma, maintained disciplined spending, and is exploring AI-enabled healthcare opportunities via potential acquisitions.

Presentation

[Operator]

Good morning and welcome to the Vyome Holdings Q3 2025 earnings call. At this time, all participants are in listen-only mode. Please note that today's discussion may include forward-looking statements, which are subject to risks and uncertainties. A full safe harbor disclosure appears in the company's press release. Now, I'd like to turn the call over to Venkat Nalabhotra, co-founder, President, and CEO of Vyome Holdings. Please go ahead.

[Venkat Nelabhotla, Co-founder, President, and CEO at Vyome Holdings]

Thank you, Shimali. Good morning, everyone. I'm very happy to share Vyome's first full reporting period as a publicly listed company. This quarter marks a significant step forward for our organization, and I'm pleased to report we are executing according to plan. We completed a streamlined NASDAQ listing with a 100% common stock structure, advanced early program VT1953 on schedule, and maintained the cost discipline central to our strategy. Our runway extends through 2026 as planned, and I'm particularly pleased to share that our disciplined spending model resulted in a lower cash burn than we had anticipated, demonstrating our operational efficiency while advancing our programs. On the team front, we strengthened our leadership by hiring a Chief Technology Officer and Senior Vice President of Clinical Development, both bringing big pharma backgrounds, deep drug development expertise, and experience across multiple FDA-approved therapies.

[Venkat Nelabhotla, Co-founder, President, and CEO at Vyome Holdings]

These additions strengthen our ability to execute on our pipeline programs. With a world-class team in place, we are focused on addressing inflammation, one of the largest challenges in global health, representing an addressable market opportunity of more than $120 billion. Our unique position, bridging the U.S. and India innovation corridors, gives us a strategic advantage. It provides access to world-class scientific talent, cost-efficient clinical trial infrastructure, and diverse patient populations, enabling us to develop therapies more rapidly and economically than traditional models while maintaining rigorous regulatory standards. Let me turn now to our lead program, VT1953. This quarter, we delivered encouraging interim phase two results for VT1953 in treating symptoms of malodor and pain of malignant fungating wounds, or MFW. We saw a significant reduction in malodor, the primary endpoint, measured by the Killer-Oder scale.

[Venkat Nelabhotla, Co-founder, President, and CEO at Vyome Holdings]

Patients also reported less lesion pain on a visual analog scale and improved quality of life. Importantly, no clinically significant adverse effects were observed with VT1953. For those unfamiliar with this condition, MFW is devastating. It affects 5%-14% of advanced cancer patients and often leads to severe emotional and social isolation due to extremely malodorous wounds that prevent interaction with family and friends. Representing a potential $1 billion addressable market opportunity in the United States, currently, there are no FDA-approved treatments for MFW. Therefore, a potentially significant demand from clinicians and patients for VT1953, with it anticipated to be the only approved drug. We are advancing it as a potential orphan drug candidate with full phase two data from our investigator-initiated trial expected in December 2025. These interim results validate our thesis that effective therapies can be developed through smartly designed and cost-efficient trials.

[Venkat Nelabhotla, Co-founder, President, and CEO at Vyome Holdings]

Moving to our second program, VT1908. We previously reported strong preclinical efficacy for VT1908 eye drops in uveitis models, reinforcing its promise as a highly needed steroid-sparing candidate. In a preclinical model of anterior uveitis, the most common form of the disease, twice daily, VT1908 eye drops significantly reduce the uveitis score. Notably, its efficacy was comparable to that of a clinically used steroid, underscoring the promise of VT1908 as a non-steroidal treatment option. FDA interactions are planned for the first half of 2026, alongside continued development activities to advance the program toward clinical readiness. Beyond our novel drug pipeline, we are also exploring the development of an AI-focused healthcare initiative through the acquisition of Oculos and MIT Spinout.

[Venkat Nelabhotla, Co-founder, President, and CEO at Vyome Holdings]

To wrap up, with our king capital structure, disciplined operations, and world-class team, we are well positioned to deliver on upcoming milestones and drive long-term value for both patients and shareholders. I'll now turn the call over to our CFO, Rob Dickey, to discuss financials.

[Rob Dickey IV, CFO at Vyome Holdings]

Thanks, Venkat, and good morning to everyone. I'll walk you through the financial highlights for the quarter ended September 30. We ended the quarter with cash, cash equivalents, and short-term investments totaling approximately $5.7 million, which we believe provides a runway through 2026, inclusive of planned clinical activities. Research and development and general administrative expenses reflect pre- and post-merger costs, and the net loss of $9.2 million primarily includes one-time transaction and non-cash financing charges associated with the merger. As noted in our press release, our outstanding common shares count stood at 5,556,295 shares, and we have no preferred stock, warrants, or convertible notes outstanding, maintaining a clean capital structure. Our disciplined spending model resulted in lower cash burn than anticipated, a development that we're pleased with given our strategic focus. Looking ahead, we remain committed to cost-efficient operations as we advance our pipeline.

[Rob Dickey IV, CFO at Vyome Holdings]

I will now turn the call back to Venkat for closing remarks.

[Venkat Nelabhotla, Co-founder, President, and CEO at Vyome Holdings]

Thanks, Rob. Today marks a defining step for Vyome. Our strategic pillars, biotech pipeline, AI-enabled healthcare, provide multiple pathways to innovation, growth, and value creation. With our programs now in motion and regulatory engagement planned for the first half of 2026, we enter the next phase with momentum and clarity. Thank you to our team, partners, and shareholders for their support. We look forward to sharing continued progress. Thank you.

[Operator]

Thank you, and that concludes today's prepared remarks. Please note that we will not be taking questions on this call. Any questions may be submitted via email to contact@vyometx.com. Thank you for your participation in Vyome Holdings Q3 2025 earnings call.

Participants

Executives

• Rob Dickey IV, CFO
• Venkat Nelabhotla, Co-founder, President, and CEO